SC
BMRN icon

Samlyn Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Samlyn Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-521,079
Closed -$44M – 111
2020
Q1 		$44M Sell
521,079
-154,291
-23% -$13.3M 1.11% 38
2019
Q4 		$57.1M Buy
675,370
+178,320
+36% +$13.5M 1.2% 30
2019
Q3 		$33.5M Buy
+497,050
New +$38.3M 0.81% 46

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Samlyn Capital's BMRN Position: Q2 2020 in Review

Samlyn Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 521,079 shares — an estimated $44M sold.

Samlyn Capital first reported a position in BMRN in Q3 2019 and held it in 3 quarters. The position peaked at $57.1M in Q4 2019. 527 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

  • Samlyn Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Samlyn Capital sold 521,079 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $44M.
  • Samlyn Capital first reported a position in BioMarin Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Samlyn Capital's BioMarin Pharmaceuticals position peaked at $57.1M in Q4 2019.
  • 527 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Samlyn Capital's 13F filing for Q2 2020, filed 14 Aug 2020.